Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.57 |
| ▸ | HTR3B | O95264 | 2/20 | 0.57 |
| ▸ | HTR3A | P46098 | 2/20 | 0.57 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.57 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | NOS3 | P29474 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | NOS2 | P35228 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5700249 | 0.78 | HTR3E (0.47) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL4533236 | 0.74 | SIGMAR1 (0.46) | LMNAMEN1CYP3A4CYP2C9MAPK1 | |
| SCHEMBL8003094 | 0.74 | CES2 (0.41) | CES2CES1ALDH1A1PBRM1NPC1 | |
| SCHEMBL5241540 | 0.73 | HTR3E (1.00) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL11869772 | 0.72 | HTR3E (0.55) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL24456383 | 0.71 | HTR3E (0.72) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Carbamic Acid SCHEMBL11869786 | 0.71 | HTR3E (0.53) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL79801 | 0.71 | SIGMAR1 (0.49) | ADRA2ACYP3A4CYP2D6CYP2C9ADRA2C | |
| SCHEMBL3121396 | 0.71 | BCAT2 (0.52) | LMNAMEN1KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL11376264 | 0.70 | CTSS (0.45) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0929553-B1 | PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2005-03-16 | — | — | EP | claimed |
| EP-0929553-A1 | PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1999-07-21 | — | — | EP | claimed |
| WO-1998014450-A1 | PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 1998-04-09 | — | — | WO | claimed |
| US-4250319-A | RIPENER FOR SUGARCANE | W. R. GRACE & CO. (US) | 1981-02-10 | — | — | US | claimed |
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-4151621-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD THEREFOR AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2023-03-22 | — | — | EP | disclosed |
| EP-0929553-B1 | PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2005-03-16 | — | — | EP | disclosed |
| EP-0929553-A1 | PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998014450-A1 | PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 1998-04-09 | — | — | WO | disclosed |
| EP-0286021-B1 | REACTIVE AZO DYES | BASF Aktiengesellschaft (DE) | 1991-06-26 | — | — | EP | disclosed |
| US-4897469-A | Aniline series azo reactive dyes ortho- or para-substituted by vinyl sulfonyl reactive groups | BASF AKTIENGESELLSCHAFT (DE) | 1990-01-30 | — | — | US | disclosed |
| EP-0286021-A2 | Reactive azo dyes | BASF Aktiengesellschaft (DE) | 1988-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | SSB, EBNA1BP2, PML | HTR3E 4840/4885HTR3B 4786/4885HTR3A 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.